Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
NCT00096473
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Adult Trials: 18+ Years
- Clinically diagnosed Alzheimer's Disease with MMSE score 1~12
- Have not been treated by any medication for Alzheimer's Disease in past 3 months
- Live in community or Assisted Living Facility
- Healthy or with chronic diseases that are medically controlled or stabilized
- Able to swallow tablets
- Any primary neurological or psychiatric diagnosis (including depressive disorder)
other than Alzheimer's Disease
- Dementia caused by organic diseases other than Alzheimer's Disease
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Northport, Alabama
- Phoenix, Arizona
- Sun City, Arizona
- Tucson, Arizona
- San Francisco, California
- Santa Monica, California
- Torrance, California
- Denver, Colorado
- Ft. Lauderdale, Florida
- Ft. Myers, Florida
- North Miami, Florida
- St. Petersburg, Florida
- Atlanta, Georgia
- Chicago, Illinois
- New Orleans, Louisiana
- Springfield, Massachusetts
- Long Branch, New Jersey
- Piscataway, New Jersey
- New Hyde Park, New York
- Greenville, North Carolina
- Raleigh, North Carolina
- Centerville, Ohio
- Oklahoma City, Oklahoma
- Medford, Oregon
- Portland, Oregon
- Jenkintown, Pennsylvania
- Austin, Texas
- Houston, Texas
- Randwick, New South Wales
- Brisbane, Queensland
- Woodville South, South Australia
- Heidelberg West, Victoria
- Nedlands, Western Australia
- Toronto, Ontario
- Paris,
- Belfast,
- St. Leonards on Sea, East Sussex
- West End, Southampton
- Swindon, Wilshire
- Bath,
- Blackpool,
- Bradford,
- New Haven, Connecticut
| Descriptive Information | |||||||
|---|---|---|---|---|---|---|---|
| Brief Title ICMJE | Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease | ||||||
| Official Title ICMJE | A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe Alzheimer's Disease Followed by a 12 Week Open-Label Extension Period | ||||||
| Brief Summary | Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD). Aricept has been shown to improve the memory and thinking abilities, activities of daily living and global function in patients. The purpose of the study is to further investigate the effectiveness and safety of donepezil in patients with severe Alzheimer's disease. Donepezil is thought to work in the brain by increasing the levels of an important brain chemical called acetylcholine. This chemical helps a person's memory to work better. | ||||||
| Detailed Description | Not Provided | ||||||
| Study Type ICMJE | Interventional | ||||||
| Study Phase ICMJE | Phase 3 | ||||||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment | ||||||
| Condition ICMJE |
| ||||||
| Intervention ICMJE | Drug: Donepezil hydrochloride | ||||||
| Study Arms ICMJE | Not Provided | ||||||
| Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
| Recruitment Information | |||||||
| Recruitment Status ICMJE | Completed | ||||||
| Actual Enrollment ICMJE | 229 | ||||||
| Original Enrollment ICMJE | 350 | ||||||
| Actual Study Completion Date ICMJE | September 2005 | ||||||
| Actual Primary Completion Date | June 2005 (Final data collection date for primary outcome measure) | ||||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| ||||||
| Sex/Gender ICMJE |
| ||||||
| Ages ICMJE | 50 Years and older (Adult, Older Adult) | ||||||
| Accepts Healthy Volunteers ICMJE | No | ||||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
| Listed Location Countries ICMJE | Australia, Canada, France, Ireland, United Kingdom, United States | ||||||
| Removed Location Countries | |||||||
| Administrative Information | |||||||
| NCT Number ICMJE | NCT00096473 | ||||||
| Other Study ID Numbers ICMJE | E2020-A001-315 | ||||||
| Has Data Monitoring Committee | Not Provided | ||||||
| U.S. FDA-regulated Product | Not Provided | ||||||
| IPD Sharing Statement ICMJE | Not Provided | ||||||
| Responsible Party | Not Provided | ||||||
| Study Sponsor ICMJE | Eisai Inc. | ||||||
| Collaborators ICMJE | Pfizer | ||||||
| Investigators ICMJE |
| ||||||
| PRS Account | Eisai Inc. | ||||||
| Verification Date | March 2011 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | |||||||